Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Total Liabilities
Everything the company owes to creditors and other parties.
Sagimet Biosciences Inc.NASDAQ: SGMT
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 26.2% from a year ago
Total liabilities stood at $5.3M at the end of Q1 FY2026, down 26.2% from a year earlier and up 3.8% from the prior quarter. Over 3 fiscal years it compounded at -71.5% a year.
Context
- Total liabilities amounted to 4.9% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -26.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.1M USD
- Year-over-year change
- +14.5%
- 4-year CAGR
- -60.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.1M | +14.5% |
| FY2024 | 2024-12-31 | 4.45M | -21.2% |
| FY2023 | 2023-12-31 | 5.65M | -97.4% |
| FY2022 | 2022-12-31 | 219.98M | +1.2% |
| FY2021 | 2021-12-31 | 217.29M | — |
Total Liabilities vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 total liabilities of $5.3M is the lowest of the 11 companies compared; the peer median is $49.85M.
- Its year-over-year change of -26.2% is the 7th highest of 11, against a peer median of -14.3%.
- Total liabilities amounts to 4.9% of total assets for SGMT, versus a peer median of 20.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.29B | +93713.8% | +2.6% | 3.9% | |
| Mar 2026 | $298.58M | -6.8% | -8.8% | 134.4% | |
| Mar 2026 | $98.93M | -21.8% | +9.0% | 89.5% | |
| Mar 2026 | $64.66M | -6.6% | +21.7% | 19.3% | |
| Mar 2026 | $54.05M | -44.9% | -31.8% | 22.0% | |
| Mar 2026 | $45.66M | -43.3% | -17.6% | 20.8% | |
| Mar 2026 | $36.9M | -48.7% | +38.5% | 15.7% | |
| Mar 2026 | $33.37M | +15.5% | +15.0% | 12.5% | |
| Mar 2026 | $22.43M | +31.3% | -2.2% | 67.7% | |
ZURAZura Bio Limited | Mar 2026 | $11.75M | -44.3% | -23.1% | 5.1% |
SGMTSagimet Biosciences Inc. | Mar 2026 | $5.3M | -26.2% | -71.5% | 4.9% |
| Peer median (excluding SGMT) | $49.85M | -14.3% | +0.2% | 20.0% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.